<Suppliers Price>

Otamixaban

Names

[ CAS No. ]:
193153-04-7

[ Name ]:
Otamixaban

[Synonym ]:
1ksn
Otamixaban
FXV-673
Methyl (2R,3R)-2-(3-carbamimidoylbenzyl)-3-{[4-(1-oxido-4-pyridinyl)benzoyl]amino}butanoate
Benzenepropanoic acid, 3-[(Z)-aminoiminomethyl]-α-[(1R)-1-[[4-(1-oxido-4-pyridinyl)benzoyl]amino]ethyl]-, methyl ester, (αR)-
UNII-S173RED00L

Biological Activity

[Description]:

Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.IC50 value:Target: Factor Xa Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery and pre-clinical data surrounding the fXa inhibitor Otamixaban as well as the recent clinical findings in humans.

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> Factor Xa
Research Areas >> Cardiovascular Disease

[References]

[1]. Eikelboom JW, Weitz JI.Otamixaban in acute coronary syndromes.Lancet. 2009 Sep 5;374(9692):762-4. Epub 2009 Aug 28.

[2]. Sabatine MS, Antman EM, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2009 Sep 5;374(9692):787-95. Epub 2009 Aug 28

[3]. Guertin KR, Choi YM.The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.Curr Med Chem. 2007;14(23):2471-81.

[4]. Cohen M, Bhatt DL, et al. SEPIA-PCI Trial Investigators.Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.Circulation. 2007

[5]. Guertin, Kevin R.; Choi, Yong-Mi.The discovery of the factor Xa inhibitor Otamixaban: from lead identification to clinical development.Current Medicinal Chemistry (2007), 14(23), 2471-2481.


[Related Small Molecules]

Fondaparinux Sodium | Betrixaban | Gabexate mesylate | Ozagrel (sodium) | RWJ-445167 | BMS-654457

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Molecular Formula ]:
C25H26N4O4

[ Molecular Weight ]:
446.498

[ Exact Mass ]:
446.195404

[ PSA ]:
130.73000

[ LogP ]:
0.58

[ Index of Refraction ]:
1.619

[ Storage condition ]:
2-8℃


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.